Last update 07 Mar 2025
Pharma& Schweiz GmbH

Pharma& Schweiz GmbH

Private Company|
2018|
Switzerland
|
10-50
|
www.pharmaand.com

Overview

Tags

Neoplasms
Urogenital Diseases
Digestive System Disorders
Small molecule drug
Interferons

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Hemic and Lymphatic Diseases3
Immune System Diseases2
Infectious Diseases2
Nervous System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug4
Interferons1
Top 5 TargetCount
PARP1 x PARP2 x PARP31
M3 receptor(Muscarinic acetylcholine receptor M3)1
IFNAR(Interferon alpha/beta receptor)1
HDACs(Histone deacetylase)1
DNA1

Related

5
Drugs associated with Pharma& Schweiz GmbH
Rucaparib Camsylate
Target
PARP1 x PARP2 x PARP3
Mechanism
PARP1 inhibitors [+2]
Active Org.
Clovis Oncology, Inc.Clovis Oncology, Inc. [+7]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Fallopian Tube Carcinoma [+25]
Inactive Indication
Advanced breast cancer [+23]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date19 Dec 2016
Panobinostat lactate
Target
HDACs
Mechanism
HDAC inhibitors
Active Org.
Biodexa Pharmaceuticals PlcBiodexa Pharmaceuticals Plc [+11]
Originator Org.
Novartis Pharma AG
Active Indication
Multiple Myeloma [+7]
Inactive Indication
Acute Graft Versus Host Disease [+95]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date23 Feb 2015
Bendamustine Hydrochloride
Target
DNA
Mechanism
DNA inhibitors
Active Org.
Cephalon, Inc.Cephalon, Inc. [+20]
Originator Org.
SymBio Pharmaceuticals Ltd.SymBio Pharmaceuticals Ltd.
Active Indication
Diffuse Large B-Cell Lymphoma [+19]
Inactive Indication
acute leukemia [+43]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date20 Mar 2008
16
Clinical Trials associated with Pharma& Schweiz GmbH
NCT04171700
/ TerminatedPhase 2
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
NCT04179396
/ CompletedPhase 1
A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03824704
/ TerminatedPhase 2
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
100 Clinical Results associated with Pharma& Schweiz GmbH
Login to view more data
0 Patents (Medical) associated with Pharma& Schweiz GmbH
Login to view more data
100 Deals associated with Pharma& Schweiz GmbH
Login to view more data
100 Translational Medicine associated with Pharma& Schweiz GmbH
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
5
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free